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Short Report

Autosomal Dominant Osteopetrosis Type II

Received: February 20, 1997

A 23 year-old man who was first seen in April 1996
gave a 8 year history of low back pain. This patient was
treated with various antiinflamatory drugs for recent
years. Father, mother and other sibships were normal and
there were no parental consaguinity.

in the ileum of the patient (Figure 1). The vertebral bone
density was assessed by quantitative computerised
tomography (QCT) and was found markedly elevated
(Figure 2). Abdominal organs ultrasonography was
normal.

On physical examination; height 170 cm, weight 66
kg were found. Dorsal and lumbar vertebra motions were
painful and limited. The other joints were normal.
Lumbar Schober, chest expansion and fingertip to floor
were fonud to be 3, 4 and 35 cm, respectively.
Neurological and otolaryngological examinations revealed
no abnormalities. Psychomotor development was normal.

Cytogenetical analyses were performed from skin
fibroblast and peripheral lymphocytes of all members in
family. The all karyotypes were found to be normal
constitution. Pedigree analysis of family has been
performed and showed no inheritance pattern.

Biochemical studies revealed a haemoglobin level of
10 gm/dL, an elevated Westergren sedimentation rate at
35 mm/hour, serum blood urea nitrogen (BUN) was 30
mg/dl, serum creatinine 0.6 mg/dl, serum calcium level
was 8.5 mg/dL, serum phosphorus level 1.3 mg/dL,
alkaline and acid phosphatase levels were 250 U/L and 12
U/L, respectively. Urine analyses showed urinary BUN
2000 mg/dL, urinary creatinine 65 mg/dL, creatinine
clearance 125 ml/min. Carbonic anhydrase II (CA II) level
was measured in erythrocyte hemolysates according to
the routine technique and was found to normal (CA II
CO2 hydratase activity was 12.5 U/mg haemoglobin) (1).
CA II levels, radiographic and laboratory examination in
the patient and other members of family were found to
be normal.
Radiographic investigations of skeletal survey showed
generalised osteosclerosis with thickened cortex, but
intracranial calcifications were not seen on skull films.
Magnetic resonance imaging (MRI) scan disclosed
osteosclerosis in superior and inferior portions of the
vertebral bodies which is produced a “sandwich”
appearance. The “bone within bone” appearance was seen

Based on standard radiographs, it is possible to
describe two different subtypes of autosomal dominant
osteopetrosis (ADO) with different clinical, biochemical,
and histologic manifestations. Type I is radiographically
characterised by pronounced osteosclerosis of the cranial
vault, whereas Type II has end-plate thickening of the
vertebrae (Rugger-Jersey spine) and endobones in the
pelvis. Patients with ADO are often asymptomatic, and
the diagnosis may be reached by chance. However, by
systematic investigations, nearly all patients have
manifestations related to the disorder. Symptoms are
progressive with age, and correlated with osteosclerosis
(2).
All forms of osteopetrosis are associated with failure
to resorb bone (3). CA II deficiency is the primary defect
in the syndrome of autosomal recessive osteopetrosis (4).
However, it is demonstrated that CA II does not seem to
play any pathogenetic role in two forms of ADO (5).
There is some variability in the severity of different
clinical manifestations in different families. In some
families, the symptoms related to the osteopetrosis
dominated the clinical picture. Previous studies suggested
that clinical heterogeneity is due to genetic heterogeneity.
Multiple genetic defects produce osteopetrosis but the
337

Autosomal Dominant Osteopetrosis Type II

Figure 1. “Bone within bone” appearance in the ileum.

Figure 2. Increased bone mineral density in QCT.

mechanism common to all the known forms of
osteopetrosis is a failure of bone resorption.

skull was most pronounced at the base, the vertebrae
always had end-plate thickening, and in the pelvis the iliac
wings contained convex arcs of sclerotic bone (6).
Biochemically, serum phosphate was found to be lower in
Type I compared to Type II, and serum acid phosphatase
was detected markedly increased in Type II (7). In the
light of these information, the present case may be
evaluated as type II ADO. Recently, the osteoclasts were
found markedly reduced in number and size in type I, but
in Type II, osteoclasts were large and highly multinucleated, with an increased number (8). Additionally,
serum carboxy-terminal propeptide of type I collagen (SPICP) was found significantly lower in type II ADO. Serum
osteocalcin values in the two type ADO were
insignificantly lower than controls (9). Unfortunately, in
present case, osteoclast morphologies and S-PICP values
could not be examinated.

In present case, CA II level was found to be normal.
However, except radiological findings and anaemia the
case not showed the other findings such as metabolic
acidosis, growth failure, mental retardation, bone
fracture, severe dental malocclusion, cerebral calcification
and visual and hearing handicaps. By considering that
normal CA II levels and absence other findings mentioned
above, present case could not be evaluated as autosomal
recessive osteopetrosis.
Interestingly, in some patients symptoms are few and
phenotypic spectrum varied from an asymptomatic
condition to a severely findings such as anemia,
hepatosplenomegaly, hydrocephalus and blindness. In
such cases, relatively benign and asymptomatic conditions
are often diagnosed as osteopetrosis by radiographycally
and other biochemical findings. The clinic picture of
present case has been evaluated as compatible with these
observations, because of he first seen in 23 years old and
had the complaint only low back pain. Biochemically,
normal CA II levels, mild anaemia, increased acid and
alkaline phosphatase levels, low plasma phosphate level,
radiologically, increased bone mineral density, “sandwich”
appearance in MRI scan of spine and “bone within bone”
appearance in the ileum were detected. Further, the
bones were diffusely osteosclerotic with thickened cortex.
According to these information, the case was evaluated as
ADO.
Andersen and Bollerslev suggested that ADO may be a
heterogeneous group. In type 1 the most striking finding
was pronounced sclerosis of the cranial vault while the
spine was almost unaffected. In type 2 the sclerosis of the
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In genetic assessment, the pedigree analysis revealed
that the condition is not inherited, because the proband
have not any relative showing similar findings, because of
this, the case may interpreted as Type II ADO resulting by
a de novo mutation. There is not satisfactory information
about the genetic etiology of ADO in literature. However,
it can speculated that, collagen and/or osteocalcin gene
mutations may contribute to etiopathogenesis of ADO.
In conclusion, we aimed to remind that ADO is a rare
condition and it may be characterised with asymptomatic
clinical picture. Because of this, some patients having only
low back pain which is the etiology is remain
undetermined must be suspect of ADO. Finally, the
present case can provide new insights to the inheritance
of ADO.
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